Search hospitals > California > Torrance
Torrance Memorial Physician Network / Cancer Care
Claim this profileTorrance, California 90505
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Tumors
Conducts research for Non-Small Cell Lung Cancer
51 reported clinical trials
14 medical researchers
Summary
Torrance Memorial Physician Network / Cancer Care is a medical facility located in Torrance, California. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Tumors, Non-Small Cell Lung Cancer and other specialties. Torrance Memorial Physician Network / Cancer Care is involved with conducting 51 clinical trials across 91 conditions. There are 14 research doctors associated with this hospital, such as Jun Gong, MD, Andrew Hendifar, MD, David Chan, M.D., and Jeremy D. Rudnick.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Cancer
Global LeaderStage IV
HER2 positive
Stage III
Top PIs
Jun Gong, MDCedars-Sinai Medical Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
35 drugs studied
Andrew Hendifar, MDCedars-Sinai Medical Center4 years of reported clinical research
Studies Pancreatic Cancer
Studies Adenocarcinoma
19 reported clinical trials
38 drugs studied
David Chan, M.D.Torrance Memorial Physician Network / Cancer Care3 years of reported clinical research
Studies Breast Cancer
Studies Cancer
16 reported clinical trials
28 drugs studied
Jeremy D. RudnickCedars-Sinai Medical Center2 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
12 reported clinical trials
26 drugs studied
Clinical Trials running at Torrance Memorial Physician Network / Cancer Care
Breast Cancer
Lung Cancer
Gallbladder Cancer
Neuroendocrine Tumors
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
Anal Squamous Cell Carcinoma
Recurrence
Anal Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Torrance Memorial Physician Network / Cancer Care?
Torrance Memorial Physician Network / Cancer Care is a medical facility located in Torrance, California. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Tumors, Non-Small Cell Lung Cancer and other specialties. Torrance Memorial Physician Network / Cancer Care is involved with conducting 51 clinical trials across 91 conditions. There are 14 research doctors associated with this hospital, such as Jun Gong, MD, Andrew Hendifar, MD, David Chan, M.D., and Jeremy D. Rudnick.